We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
+23.47%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.49B
AUM Growth
+$497M
Cap. Flow
+$426M
Cap. Flow %
12.21%
Top 10 Hldgs %
38.36%
Holding
80
New
20
Increased
14
Reduced
16
Closed
14

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$161M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$139M
3
APLS
Apellis Pharmaceuticals
APLS
+$63.7M
4
DYN icon
Dyne Therapeutics
DYN
+$57.8M
5
NTLA icon
Intellia Therapeutics
NTLA
+$54.5M

Top Sells

Rank Stock Value
1
AMAM
Ambrx Biopharma Inc
AMAM
+$52.8M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$48.2M
3
RAPT
RAPT Therapeutics
RAPT
+$44.6M
4
ACLX
Arcellx
ACLX
+$40.2M
5
ANAB icon
AnaptysBio
ANAB
+$35.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.65%
2 Miscellaneous 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVTX icon
26
Travere Therapeutics
TVTX
$6B
$56.8M 1.63%
7,370,000
– –
VRNA
27
DELISTED
Verona Pharma
VRNA
$51.3M 1.47%
3,187,415
– –
KYMR icon
28
Kymera Therapeutics
KYMR
$9.69B
$50.7M 1.45%
+1,262,246
New +$45.2M
IVVD icon
29
Invivyd
IVVD
$240M
$48.6M 1.39%
+10,953,937
New +$45.3M
SYRE icon
30
Spyre Therapeutics
SYRE
$8.09B
$46M 1.32%
1,213,420
-739,340
-38% -$21.4M
NRIX icon
31
Nurix Therapeutics
NRIX
$2.6B
$44.1M 1.26%
2,997,830
– –
HLVX
32
DELISTED
HilleVax
HLVX
$42.8M 1.23%
2,572,460
-327,540
-11% -$5.24M
EDIT icon
33
Editas Medicine
EDIT
$415M
$41M 1.17%
5,527,290
+54,204
+1% +$450K
FATE icon
34
Fate Therapeutics
FATE
$288M
$40.9M 1.17%
+5,572,607
New +$34.5M
TERN
35
DELISTED
Terns Pharmaceuticals
TERN
$40M 1.15%
6,100,000
– –
ENGN icon
36
enGene Therapeutics
ENGN
$127M
$38.1M 1.09%
+2,250,000
New +$27.5M
TRML
37
DELISTED
Tourmaline Bio
TRML
$36.5M 1.05%
1,595,400
-220,454
-12% -$7.77M
OLMA icon
38
Olema Pharmaceuticals
OLMA
$846M
$36.5M 1.05%
3,225,419
+1,294,525
+67% +$16.7M
SLN
39
Silence Therapeutics
SLN
$773M
$35.5M 1.02%
1,643,881
-307,699
-16% -$6.69M
PACB icon
40
Pacific Biosciences
PACB
$426M
$26.3M 0.75%
7,000,000
– –
HELP
41
Cybin Inc
HELP
$989M
$24M 0.69%
+1,529,988
New +$22.1M
ALEC icon
42
Alector
ALEC
$222M
$22.7M 0.65%
+3,769,386
New +$24.6M
NUVL
43
DELISTED
Nuvalent
NUVL
$20.6M 0.59%
274,512
-175,488
-39% -$14M
AGEN
44
Agenus
AGEN
$321M
$18.4M 0.53%
1,584,877
– –
PYXS icon
45
Pyxis Oncology
PYXS
$279M
$17.8M 0.51%
+4,184,100
New +$17.6M
NKTR icon
46
Nektar Therapeutics
NKTR
$2.28B
$17.2M 0.49%
1,226,667
– –
IMVT icon
47
Immunovant
IMVT
$7.69B
$15.9M 0.46%
493,352
-506,648
-51% -$18.5M
NMRA icon
48
Neumora Therapeutics
NMRA
$150M
$13.8M 0.39%
+1,000,000
New +$16.2M
RPTX
49
DELISTED
Repare Therapeutics
RPTX
$12.6M 0.36%
2,684,344
-308,387
-10% -$1.98M
ITCI
50
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$12.1M 0.35%
+175,400
New +$12.1M
1
2
3 4

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Deep Track Capital held 80 positions worth $3.49B, up 17% from $2.99B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Deep Track Capital deployed $426M of net new capital in Q1 2024, opening 20 new positions and adding to 14 existing holdings. Its largest new stake was Amgen: 550,000 shares worth $156M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was AnaptysBio, an estimated $35.7M trimmed.

  • Deep Track Capital's largest Q1 2024 buy was Amgen: 550,000 shares worth $156M.
  • Deep Track Capital added most to Dyne Therapeutics in Q1 2024, an estimated $57.8M increase.
  • Deep Track Capital's biggest Q1 2024 reduction was AnaptysBio, cutting an estimated $35.7M.
  • Deep Track Capital fully exited Ambrx Biopharma Inc in Q1 2024, selling an estimated $52.8M.
  • Deep Track Capital's ten largest holdings make up 38% of its $3.49B portfolio in Q1 2024.
  • Deep Track Capital opened 20 new positions and closed 14 in Q1 2024.
  • Deep Track Capital's portfolio value rose 17% quarter-over-quarter to $3.49B.

Based on Deep Track Capital's 13F filing for Q1 2024, filed 15 May 2024.